Evidence map›Paper›PMID 36584927›Full record

ArticleTransplant immunology2023

The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.

Ken Arimura, Etsuko Tagaya, Ken Kikuchi, Toshihiro Mitsuda, Fumiya Ebihara, Takumi Maruyama, Yukihiro Hamada, Kohei Unagami, Taichi Kanzawa, Haruki Sekiguchi and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ken ArimuraDepartment of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan. Electronic address: arimuraken@gmail.com.
Etsuko TagayaDepartment of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ken KikuchiDepartment of Infectious Diseases, Tokyo Women's Medical University, Tokyo, Japan.
Toshihiro MitsudaDepartment of Infection Prevention and Control, Tokyo Women's Medical University, Tokyo, Japan.
Fumiya EbiharaDepartment of Pharmacy, Tokyo Women's Medical University, Tokyo, Japan.
Takumi MaruyamaDepartment of Pharmacy, Tokyo Women's Medical University, Tokyo, Japan.
Yukihiro HamadaDepartment of Pharmacy, Tokyo Women's Medical University, Tokyo, Japan.
Kohei UnagamiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Taichi KanzawaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Haruki SekiguchiDepartment of General Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ken ShimamotoDepartment of General Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Hideki IshidaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Hiroto EgawaDepartment of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Masatoshi KawanaDepartment of General Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTransplant recipients (TRs) are at high risk for severe coronavirus disease 2019 (COVID-19). Neutralizing monoclonal antibodies (mAbs) are used for treating mild-to-moderate COVID-19. However, reports comparing the efficacy of COVID-19 treatment without/with mAbs in TRs are limited. We assessed the efficacy of casirivimab/imdevimab against mild-to-moderate COVID-19 in TRs.

methodsForty-one patients were retrospectively evaluated. The duration until defervescence, oxygen (O

resultsCasirivimab/imdevimab was correlated with shorter duration until defervescence and non-requirement of O

conclusionCasirivimab/imdevimab was effective and increased the neutralizing antibody in TRs with mild-to-moderate COVID-19, it may contribute toward preventing the progression.

Indexed as

Antibodies, MonoclonalCOVID-19Antibodies, NeutralizingCOVID-19 Drug TreatmentHumansOxygenRetrospective StudiesTransplant RecipientsAntibodies, MonoclonalAntibodies, NeutralizingOxygenCasirivimab/imdevimabCOVID-19Neutralizing antibodySARS-CoV-2TRs

Identifiers

PMID36584927
PMCPMC9796351
OpenAlexW4313206307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.